Olanzapine | Market Size, Share & Growth Report 2025-2029
The Olanzapine Market Report is Segmented by Product Type (Oral Tablets, Orally Disintegrating Tablets, and Injectable), Application (Schizophrenia, Bipolar Disorder, Depression, Alzheimer's Disease, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Ingredient Type (Generic and Branded).
Olanzapine Market
Market Analysis
How the market stands today, and what is shaping it
The global olanzapine market was estimated at approximately USD 2.98 billion in 2025 and is projected to reach around USD 2.98 billion by 2029, representing a CAGR of approximately 0.00% during 2025–2029, based on Core Market Research estimates. The market supplies a single second-generation antipsychotic, approved in the United States in 1996 and generic since 2011, as oral tablets, orally disintegrating tablets and an intramuscular depot, with a fixed olanzapine-samidorphan combination as the one branded oral option. Growth is supported by maintenance treatment of schizophrenia and bipolar I disorder, by guideline-recommended antiemetic use in highly emetogenic chemotherapy, and by branded sales that rose to USD 346.7 million in 2025. Expansion is constrained by commodity generic pricing that absorbs volume gains, by weight gain and metabolic effects intrinsic to the molecule, and by a boxed warning restricting the existing depot to registered facilities. Competition turns on formulation and delivery rights rather than on the compound, which all participants share since generic entry in 2011. The clearest current signal is FDA acceptance on 20 February 2026 of a once-monthly subcutaneous injectable that recorded no post-injection delirium in phase 3.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Schizophrenia and bipolar I disorder require maintenance treatment measured in years rather than courses, and olanzapine remains among the more effective options for both. Each patient retained on therapy therefore converts into continuing dispensed volume, which is why prescription counts hold up even where revenue does not.
- A once-monthly subcutaneous long-acting injectable using MedinCell's SteadyTeq copolymer recorded no post-injection delirium or sedation across 3,470 injections through 56 weeks in the phase 3 SOLARIS trial. Removing that syndrome would remove the reason depot olanzapine is confined to registered facilities.
- The FDA accepted the application for that injectable on 20 February 2026, moving it from development into review. Regulatory acceptance is what converts a formulation advantage into a product that can be prescribed, and no competing olanzapine depot without the warning is in review.
- Generic oral olanzapine has been priced at commodity levels since patent expiry in 2011, which removes cost as a barrier to initiation and keeps the molecule on formularies with few restrictions. Access is therefore broad, and the constraint on revenue sits with price rather than with coverage.
- LYBALVI net sales reached USD 346.7 million in 2025, up from USD 280.0 million in 2024, with 2026 guidance of USD 380 million to USD 400 million. That growth comes from adding an opioid antagonist to limit weight gain rather than from any change to the antipsychotic itself.
Market Challenges
- The stored forecast holds the market at USD 2.98 billion from 2025 through 2029, a 0.00% compound rate. Generic pricing since 2011 offsets volume growth so completely that branded gains of the size disclosed by LYBALVI do not move the total, and no reconciliation of the two was available.
- Weight gain and metabolic effects are the reason olanzapine is not used more widely despite its efficacy. One marketed product addresses this by adding samidorphan, but the underlying liability belongs to the molecule and is present in the generic presentations that carry most of the volume since 2011.
- The existing depot carries a boxed warning for post-injection delirium and sedation syndrome and can be given only in a registered facility with three hours of observation after each dose. That requirement, not clinical preference, is what has kept long-acting olanzapine a small segment.
- Olanzapine is not approved for dementia-related psychosis and its label carries a boxed warning of increased mortality in elderly patients treated for it. One of the five supplied Application values, Alzheimer's Disease, therefore describes use that runs against an explicit safety warning rather than a market.
- Every marketed product in this market delivers the same active molecule first approved in 1996. Differentiation depends on what is added around it, so a competitor can be answered only by another formulation rather than by a better compound, which narrows the ways any participant can grow.
Opportunities
- Approval of the once-monthly subcutaneous injectable could open long-acting olanzapine to settings that cannot provide three hours of supervised observation. That would be the first expansion of the injectable segment since the existing depot was approved in 2009.
- The olanzapine-fluoxetine combination for treatment-resistant and bipolar depression is an approved but comparatively small use. Wider recognition of that indication could extend the molecule into a population currently reached mainly by other agents.
- Antiemetic use under the NCCN, ASCO and MASCC-ESMO guidelines may continue to grow in volume as four-drug regimens spread. It could become commercially meaningful only if a formulation priced above generic tablets were developed for that setting.
- Manufacturing consolidation at a single Korean campus supplying 46 countries may lower the cost of serving smaller markets, which could make branded supply viable in territories where it has not been established.
- A delivery technology that removes a boxed warning from an old molecule has potential application beyond olanzapine, and the copolymer platform behind the pending injectable could support further long-acting psychiatric products if this first application is approved.
Trends and Insights
Key market trends shaping the industry landscape
Value Is Migrating From Molecule to Delivery
High impactMid-termBoth branded products competing in this market add something around olanzapine rather than changing it: an opioid antagonist in one case, a copolymer delivery system in the other.
Insight: Where the active ingredient is a cheap generic, the defensible asset becomes the formulation, so the companies that matter are those holding delivery technology rather than those holding the compound.
A Boxed Warning as the Competitive Target
High impactShort-termThe pending injectable is positioned primarily on the absence of post-injection delirium and sedation, a syndrome that has restricted the existing depot since 2009.
Insight: Competition here is aimed at a regulatory restriction rather than at a clinical endpoint, which is unusual and means approval alone would redraw the injectable segment.
The Originator Has Left
Medium impactMid-termWorldwide rights to the originator brand passed from its developer to a brand-acquisition specialist in 2023, and manufacturing has moved to a contract producer in Korea.
Insight: A mature brand is now owned and made by companies whose business is operating late-lifecycle assets efficiently, which suggests price and supply cost, not development, will drive its remaining value.
Guideline Use Outside the Label
Medium impactMid-termThree international antiemetic guidelines recommend olanzapine within four-drug regimens for highly emetogenic chemotherapy, an indication the product is not approved for.
Insight: Prescription volume in this market is no longer bounded by its approved indications, which makes volume a poor proxy for the psychiatric market the forecast describes.
Flat Revenue Over Rising Volume
High impactLong-termThe stored forecast holds total value unchanged through 2029 while disclosed branded sales grow and guideline-driven volume expands.
Insight: A flat total implies generic price erosion is expected to absorb all branded and volume gains, which is a strong assumption that the disclosed figures do not by themselves support.
Segment Analysis
Market segmentation by product type, application, distribution channel, ingredient type
Oral Tablets carry the volume and almost none of the value, because generic entry in 2011 removed the price that once sat behind them. Orally Disintegrating Tablets exist for a specific clinical problem rather than as a convenience format: they are used where a patient cannot reliably be observed swallowing a dose, which matters in acute psychiatric settings. Injectable is where the commercial contest now sits, and it is the smallest of the three by volume. The existing depot, olanzapine pamoate, requires a registered facility and three hours of post-dose observation, which restricts it to sites able to provide that. A once-monthly subcutaneous long-acting injectable is under FDA review after acceptance on 20 February 2026, and it would remove that restriction if approved.
Geography Analysis
Regional market analysis
North America
LYBALVI net sales rose 23.8% to USD 346.7 million in 2025, the only quantified regional revenue growth identified anywhere in this market. That product is sold in the United States, so the figure is a United States number rather than a global one. The regional ranking rests on documented regulatory and commercial concentration rather than on a measured regional market size. Olanzapine was first approved here in 1996, and the depot restriction that shapes the injectable segment is an FDA requirement. The pending once-monthly injectable is under FDA review following acceptance on 20 February 2026. Guideline-driven antiemetic use also originates here, through NCCN and ASCO recommendations. The region therefore sets both the safety constraint and the route out of it, while the underlying oral molecule earns generic prices.
Europe
Europe holds the originator brand and the delivery technology without holding the largest commercial market. CHEPLAPHARM, based in Germany, has owned worldwide commercial rights to Zyprexa since closing its USD 1.4 billion purchase from Eli Lilly on 24 July 2023, so decisions about the originator brand are now taken from Europe rather than from the United States. MedinCell, based in France, supplies the SteadyTeq copolymer technology behind the once-monthly subcutaneous injectable under review. Europe is consequently upstream of the market in two senses, owning the brand and the formulation science, while the revenue those assets generate is realised elsewhere. No European market size or growth figure was identified.
Asia Pacific
Asia Pacific has become the manufacturing base for the originator brand. Boryung obtained Korean rights to Zyprexa in 2021 and brought production in-house after technology transfer and bioequivalence verification. On 17 July 2025 it signed its first global CDMO contract for oral formulations, supplying Zyprexa tablets to 46 countries including markets in Europe and North America from its Yesan campus, with supply starting in the fourth quarter of 2025. That arrangement inverts the usual regional pattern, because the region is exporting the branded product into the markets that consume it rather than importing it. The Yesan site holds EU-GMP certification for injectable anticancer products obtained in 2023 and is pursuing further certifications for its oral line.
Latin America
No market size, prescribing rate or access study specific to Latin America was identified for olanzapine, and that absence is the main finding for the region. One concrete link exists. The Korean manufacturing site now supplying Zyprexa to 46 countries is pursuing certification from Brazil's ANVISA for its oral line, alongside European and United States certifications, which indicates that branded supply into the region is being prepared rather than already established. Beyond that, the region is served by generic olanzapine whose pricing has been at commodity levels since 2011, and no regional revenue disclosure was found from any company examined. The commercial contest described elsewhere in this report, between tolerability-improved and delivery-improved branded products, has no identified presence here.
Middle East & Africa
The region's relevance is as a corporate base rather than as a consumption market. Teva Pharmaceutical Industries is headquartered in Israel, and it is both a large supplier of generic olanzapine and the sponsor of the once-monthly subcutaneous injectable whose application the FDA accepted on 20 February 2026. A company in this region therefore stands on both sides of the market at once, supplying the commodity form and developing the product intended to move value away from it. No market size, prescribing or access figure specific to the Middle East and Africa was identified for olanzapine, and no regional programme was found among the companies examined.
Competitive Landscape
Key players and market positioning analysis
Competition here is unusual because no participant differentiates on the active ingredient. Olanzapine has been in use since its 1996 United States approval and has been generic since 2011, so every marketed product delivers the same molecule and competes on what surrounds it. Alkermes plc holds the only branded position with disclosed revenue, marketing LYBALVI, a fixed combination of olanzapine and the opioid antagonist samidorphan approved on 28 May 2021 for schizophrenia and bipolar I disorder. LYBALVI net sales were USD 346.7 million in 2025 against USD 280.0 million in 2024, with guidance of USD 380 million to USD 400 million for 2026. Its proposition is tolerability, specifically less weight gain than olanzapine alone. CHEPLAPHARM Arzneimittel GmbH owns the originator brand, having bought worldwide commercial rights to Zyprexa from Eli Lilly and Company for USD 1.4 billion in a deal agreed on 21 April 2023 and closed on 24 July 2023. Eli Lilly, which developed olanzapine, is no longer a participant, having sold those rights outright, and appears here only as the originator. Teva Pharmaceutical Industries Ltd. occupies both ends of the market at once, as a large supplier of generic olanzapine and as sponsor of the once-monthly subcutaneous long-acting injectable whose application the FDA accepted on 20 February 2026. MedinCell S.A. supplies the SteadyTeq copolymer technology that product depends on, and participates through that technology rather than through supply. Boryung Corporation holds Korean rights obtained in 2021 and, under a contract signed on 17 July 2025, manufactures Zyprexa tablets for 46 countries from its Yesan campus. The principal competitive factors are formulation rights, delivery technology and manufacturing cost. Clinical differentiation on the molecule itself is not available to anyone.
Major Players
Leading companies in the market
Industry Developments
9 recorded developments
The FDA accepted that application on 20 February 2026. Acceptance moved the first olanzapine depot without a post-injection delirium warning from development into regulatory review, which is the clearest near-term change identified in this market.
Boryung signed its first global CDMO contract for oral formulations with CHEPLAPHARM on 17 July 2025, supplying Zyprexa tablets to 46 countries including markets in Europe and North America from its Yesan campus, with supply beginning in the fourth quarter of 2025.
Teva submitted a New Drug Application to the FDA on 9 December 2025 for olanzapine extended-release injectable suspension, a once-monthly subcutaneous long-acting injectable developed with MedinCell's SteadyTeq copolymer technology.
CHEPLAPHARM agreed on 21 April 2023 to acquire worldwide commercial rights to Zyprexa from Eli Lilly and Company for USD 1.4 billion, closing on 24 July 2023. Lilly received USD 1.05 billion in cash plus USD 305 million at the first anniversary and up to USD 50 million in milestones.
The FDA approved LYBALVI, a fixed combination of olanzapine with the opioid antagonist samidorphan, on 28 May 2021 for schizophrenia and bipolar I disorder. It was the first branded olanzapine product in a decade to compete on tolerability rather than on efficacy.
Boryung obtained Korean rights to Zyprexa in 2021 and moved to in-house production after technology transfer and bioequivalence verification. Manufacturing of the originator brand began shifting away from its originator.
United States patent protection on oral olanzapine lapsed and generic entry followed. Price fell to generic levels across the oral presentations, which is the single largest reason a market with rising prescription volume shows no revenue growth.
The FDA approved Zyprexa Relprevv, an olanzapine pamoate depot given intramuscularly, with a boxed warning for post-injection delirium and sedation syndrome. It can be dispensed only through a restricted programme requiring a registered facility and three hours of observation after each dose.
Olanzapine received its initial United States approval in 1996 as Zyprexa. All marketed products are formulations of a molecule in clinical use since 1996, which is why differentiation now happens through delivery rather than through the active ingredient.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Ingredient Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Alkermes plc
9.2 CHEPLAPHARM Arzneimittel GmbH
9.3 Teva Pharmaceutical Industries Ltd.
9.4 Boryung Corporation
9.5 MedinCell S.A.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2029
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Alkermes plc, CHEPLAPHARM Arzneimittel GmbH, Teva Pharmaceutical Industries Ltd., Boryung Corporation + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.